Exoxemis Exoxemis - Publications
Home Technology Indications Collaborations Company Publications Contact
 
>

Posters

 
       
>

News

Exoxemis’ scientific team members are active contributors to the field’s body of knowledge in MPO technology.

 
       
>

Haloperoxidase Literature

An extensive literature on haloperoxidases supports the broad microbicidal activity of MPO and EPO. more >>

   
       
>

E-mail Inquiries

   

News

February 23, 2005

Exoxemis Presents at the 51st Annual Meeting of the Orthopedic Research Society

Exoxemis, Inc. (Little Rock, AR) presented data this week at the 51st annual meeting of the Orthopedic Research Society demonstrating the in vivo efficacy of its myeloperoxidase (MPO) enzyme system in a rat model of surgical site infection.

The data presented demonstrates the progress that has been made in developing and validating the MPO system for preventing surgical site infection. A rat dermal model was used to mimic the situation of contaminated wound margins that is believed to cause the majority of surgical site infections in human patients. Complete and rapid kill of concentrated (106) Staphylococcus aureus inoculum was demonstrated within 15 minutes using MPO compared to no kill with the control solution.

Surgical site infections are an important cause of hospital morbidity, mortality and excess cost. Even a very small amount of inoculum can cause infection in certain hosts. The MPO system is an oxidant generating enzyme system that is being developed as a local agent to prevent surgical site infection. In vitro, the system has demonstrated rapid microbicidal activity against a wide range of organisms even in the presence of implant materials.

Exoxemis, Inc. (Little Rock, Arkansas), a biopharmaceutical research and development company, develops haloperoxidase products for prevention and treatment of serious infections to address the growing problem of microbial drug resistance. The rapid microbicidal activity and favorable safety profile of the MPO system suggest promising applications in a wide variety of therapeutic areas. The Exoxemis technology is a versatile platform that can be leveraged into multiple product areas, including medical, biodefense, industrial, veterinary and agricultural applications. For further information, contact medinfo@exoxemis.com.


November 1, 2004

Exoxemis, Inc. (Little Rock, Arkansas) presents research results of animal safety profile of pure and formulated porcine myeloperoxidase at the 4th International Peroxidase Meeting, Kyoto, Japan, October 27-30, 2004.

A cell free oxidant generating system containing porcine myeloperoxidase (MPO) has been developed as a local/topical antimicrobial. Recent studies conducted by Exoxemis, Inc. demonstrated that the MPO system is rapidly microbicidal against a broad range of bacteria, fungi, spores, and viruses in vitro, and demonstrates rapid decrease in bacterial challenge after application onto wounds in vivo. Excellent efficacy of the MPO system both in vitro and in vivo led us to investigate the safety profile of the pure and formulated MPO.

Studies were conducted in rats and rabbits to investigate the safety of pure and formulated MPO. The studies included 14 day oral, dermal and pulmonary toxicity testing and 72 hour dermal and ocular irritation testing. The results showed that pure and formulated MPO were non-toxic in oral, dermal and pulmonary tests and non-irritating to the eyes. In dermal irritation tests, a slight and transient erythema reaction in 1/3 rabbits cleared within 24 hours. The results support previous in vitro and in vivo studies indicating that MPO and MPO formulations are non-toxic, non-irritating, non-genotoxic, and non-sensitizing.

Exoxemis, Inc. (Little Rock, Arkansas), a biopharmaceutical research and development company, develops haloperoxidase products for prevention and treatment of serious infections, and to address the growing problem of microbial drug resistance. The rapid microbicidal activity and favorable safety profile of the MPO system suggest promising applications in a wide variety of therapeutic areas. The Exoxemis technology is a versatile platform that can be leveraged into multiple product areas, including medical, biodefense, industrial, veterinary and agricultural applications. For further information, contact medinfo@exoxemis.com.


February 15, 2004.

Exoxemis, Inc. (Little Rock, Arkansas) presents research results comparing the Myeloperoxidase (MPO) Enzyme System to antibiotics for irrigation of implant material at the Orthopaedic Research Society (ORS), San Francisco, CA, March 7 – 10, 2004.

Residual bacteria at the site of implant surgery can lead to acute and delayed infection. Recent studies conducted by Exoxemis, Inc. clearly demonstrated that the MPO enzyme system rapidly and completely kills residual S. aureus, even in the presence of implant material. Antibiotic solutions traditionally used in the clinic failed to do so, and in fact showed re-growth of the initial inoculum. Dr. Anthony Robins, a co-investigator and orthopedic surgeon at University of Washington (Seattle, Washington) commented, “This new method demonstrates superiority over the current clinical practice in vitro for reducing residual bacteria.”

Exoxemis, Inc. (Little Rock, Arkansas), a biopharmaceutical research and development company, develops haloperoxidase products for prevention and treatment of serious infections, and to address the growing problem of microbial drug resistance. The Exoxemis technology is a versatile platform that can be leveraged into multiple product areas, including medical, biodefense, industrial, veterinary and agricultural applications. For further information, contact medinfo@exoxemis.com.


Read excerpts from reports about Exoxemis in the news.

January 20, 2004

Cleveland Clinic hopes to sell diagnostic test for heart attack detection.

Cleveland (AP). The Cleveland Clinic has received $6 million from Exoxemis, Inc. of Little Rock, Arkansas to help develop and sell diagnostic tests, including a blood test that could determine if someone is at risk for having a heart attack.

The new company is named PrognostiX and is expected to be operational in April. The main product will be a blood test designed to identify patients at risk of having a heart attack by measuring the level of myeloperoxidase, or MPO, found in the bloodstream. MPO is an enzyme found in disease-fighting white blood cells.

Dr. Stanley Hazen's research at the clinic shows that an elevated level of MPO could signal a person's risk for having heart disease or a heart attack. His findings were published in October 2003 in the New England Journal of Medicine.